P1269: VIP152 IS A NOVEL CDK9 INHIBITOR WITH IMPROVED SELECTIVITY, TARGET MODULATION, AND CARDIAC SAFETY IN PATIENTS WITH LYMPHOMA

• M. Frigault,
• S. Sher,
• J. Ravikrishnan,
• R. Izumi,
• J. Ware,
• H. Wong,
• A. Johnson,
• B. Stelte-Ludwig,
• J. Byrd,
• D. Sampath,
• K. Rogers,
• J. Woyach,
• R. Lapalombella,
• A. Hamdy

Affiliations

M. Frigault

1 Vincerx Pharma, Palo Alto

S. Sher

2 The Ohio State University, Columbus, United States of America

J. Ravikrishnan

2 The Ohio State University, Columbus, United States of America

R. Izumi

1 Vincerx Pharma, Palo Alto

J. Ware

1 Vincerx Pharma, Palo Alto

H. Wong

1 Vincerx Pharma, Palo Alto

A. Johnson

1 Vincerx Pharma, Palo Alto

B. Stelte-Ludwig

3 Vincerx Pharma, Monheim, Germany

J. Byrd

4 University of Cincinnati, Cincinnati

D. Sampath

5 MD Anderson, Houston, United States of America

K. Rogers

2 The Ohio State University, Columbus, United States of America

J. Woyach

2 The Ohio State University, Columbus, United States of America

R. Lapalombella

2 The Ohio State University, Columbus, United States of America

A. Hamdy

1 Vincerx Pharma, Palo Alto